News and Press Releases

Yu Joins FTI as Director of Process Chemistry

Thursday, August 1, 2002
Download this FTI news release (PDF).

Fluorous Technologies, Inc. (FTI) today announces the addition of Dr. Marvin S. Yu to its management team. Dr. Yu joins FTI as Director of Process Chemistry, responsible for all laboratory efforts focused on chemistry of scale.

"The hiring of Dr. Yu represents an important addition to our scientific staff, said Dr. Philip E. Yeske, Chief Operating Officer of FTI. Dr. Yeske went on to say, "Fluorous chemistry is by no means limited in its utility to early stage drug discovery, so it is wonderful that a process chemist of Dr. Yu's ability has joined on to help drive the chemical development portion of our business. I look forward to working closely with him as we strategically enter this market segment."

Dr. Yu received his S.B. in Chemistry from MIT in 1986, followed by his Ph.D. from Emory University in 1991, under the direction of Professor Lanny Liebeskind. He then joined Professor Dennis Curran at the University of Pittsburgh as a postdoctoral fellow. In 1994, Dr. Yu joined the Synthetic Chemistry Department at GlaxoSmithKline. His responsibilities included the design and development of efficient synthetic routes to drug candidates, preclinical drug substance project management, and group leadership.

"The potential for fluorous chemistry to make a revolutionary impact on drug discovery and development is tremendous. I am excited at the prospects of providing my knowledge and experience to augment an already great team at FTI to realize that potential" said Dr. Yu.

FTI (www.fluorous.com) is a Pittsburgh-based chemical technology company focused on the life sciences market. For further information please contact us at bizdev@fluorous.com.

Statements herein that are not descriptions of historical facts are forward-looking and subject to risk and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors, including risks relating to the early stage of products under development; uncertainties related to patent protection; dependence on third parties, including strategic partners, collaborators and key personnel; future capital needs; and risks relating to the development and commercialization, if any, of Fluorous Technologies' proposed products (such as marketing, manufacturing, safety, regulatory, patent or product liability, supply, competition and other risks).